Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 659

1.

Developments on antibiotics for multidrug resistant bacterial Gram-negative infections.

Voulgaris GL, Voulgari ML, Falagas ME.

Expert Rev Anti Infect Ther. 2019 Jun;17(6):387-401. doi: 10.1080/14787210.2019.1610392. Epub 2019 May 27.

PMID:
31006284
2.

Synergistic activity of colistin with azidothymidine against colistin-resistant Klebsiella pneumoniae clinical isolates collected from inpatients in Greek hospitals.

Falagas ME, Voulgaris GL, Tryfinopoulou K, Giakkoupi P, Kyriakidou M, Vatopoulos A, Coates A, Hu Y; Colistin - Azidothymidine Hellenic Study Group.

Int J Antimicrob Agents. 2019 Jun;53(6):855-858. doi: 10.1016/j.ijantimicag.2019.02.021. Epub 2019 Mar 2.

PMID:
30836109
3.

Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gram-negative infections: A systematic review.

Vardakas KZ, Athanassaki F, Pitiriga V, Falagas ME.

J Glob Antimicrob Resist. 2019 Jun;17:250-259. doi: 10.1016/j.jgar.2019.01.004. Epub 2019 Jan 15. Review.

PMID:
30658202
4.

Fluoroquinolone-based versus β-lactam-based regimens for complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.

Mavros MN, Theochari NA, Kyriakidou M, Economopoulos KP, Sava JA, Falagas ME.

Int J Antimicrob Agents. 2019 Jun;53(6):746-754. doi: 10.1016/j.ijantimicag.2019.01.004. Epub 2019 Jan 10. Review.

PMID:
30639629
5.

Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.

Chorepsima S, Kechagias KS, Kalimeris G, Triarides NA, Falagas ME.

Drug Des Devel Ther. 2018 Nov 27;12:4059-4066. doi: 10.2147/DDDT.S168014. eCollection 2018. Review.

6.

A Model for Out-of-Hospital Multispecialty Emergency Medicine: Accomplishments and Challenges.

Theocharis G, Kechagias KS, Oikonomou M, Chorepsima S, Rodis D, Salpigktis I, Falagas ME.

Health Serv Insights. 2018 Oct 23;11:1178632918805996. doi: 10.1177/1178632918805996. eCollection 2018.

7.

Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences.

Falagas ME, Athanasaki F, Voulgaris GL, Triarides NA, Vardakas KZ.

Int J Antimicrob Agents. 2019 Jan;53(1):22-28. doi: 10.1016/j.ijantimicag.2018.09.013. Epub 2018 Sep 27. Review.

PMID:
30268576
8.

Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.

Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Falagas ME, Salvatore S, Protopapas A, Loutradis D.

Menopause. 2019 Mar;26(3):248-255. doi: 10.1097/GME.0000000000001206.

PMID:
30252804
9.

Efficacy of vaginal therapies alternative to vaginal estrogens on sexual function and orgasm of menopausal women: A systematic review and meta-analysis of randomized controlled trials.

Pitsouni E, Grigoriadis T, Douskos A, Kyriakidou M, Falagas ME, Athanasiou S.

Eur J Obstet Gynecol Reprod Biol. 2018 Oct;229:45-56. doi: 10.1016/j.ejogrb.2018.08.008. Epub 2018 Aug 6.

PMID:
30103082
10.

An analysis of medical visits at a primary health care center in Kinshasa, Democratic Republic of the Congo (DRC).

Dandoulakis M, Mavroudis AD, Karagianni A, Stefani S, Falagas ME.

Eur J Intern Med. 2018 Jul;53:e19-e20. doi: 10.1016/j.ejim.2018.05.021. No abstract available.

PMID:
29929819
11.

Patient house calls in Attica and Thessaloniki, Greece (2005-2015): a model for out-of-hospital multispecialty emergency medicine.

Theocharis G, Barbas SG, Spiropoulos T, Stamouli PE, Perdikis DN, Falagas ME.

BMC Health Serv Res. 2018 Apr 27;18(1):304. doi: 10.1186/s12913-018-3111-0.

12.

An update on adverse drug reactions related to β-lactam antibiotics.

Vardakas KZ, Kalimeris GD, Triarides NA, Falagas ME.

Expert Opin Drug Saf. 2018 May;17(5):499-508. doi: 10.1080/14740338.2018.1462334. Epub 2018 Apr 18. Review.

PMID:
29633867
13.

Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.

Falagas ME, Skalidis T, Vardakas KZ, Voulgaris GL, Papanikolaou G, Legakis N; Hellenic TP-6076 Study Group.

Int J Antimicrob Agents. 2018 Aug;52(2):269-271. doi: 10.1016/j.ijantimicag.2018.03.009. Epub 2018 Mar 17.

PMID:
29559273
14.

Temporal Trends (1999-2015) in the Impact Factor of Biomedical Journals Published by US and EU Scientific Societies.

Falagas ME, Kyriakidou M, Spais G, Argiti E, Vardakas KZ.

Rambam Maimonides Med J. 2018 Apr 19;9(2). doi: 10.5041/RMMJ.10332.

15.

Intravenous plus inhaled versus intravenous colistin monotherapy for lower respiratory tract infections: A systematic review and meta-analysis.

Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME.

J Infect. 2018 Apr;76(4):321-327. doi: 10.1016/j.jinf.2018.02.002. Epub 2018 Feb 8. Review.

PMID:
29428226
16.

Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis.

Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME.

Int J Antimicrob Agents. 2018 Apr;51(4):535-547. doi: 10.1016/j.ijantimicag.2017.12.020. Epub 2017 Dec 27. Review.

PMID:
29288723
17.

Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.

Vardakas KZ, Voulgaris GL, Maliaros A, Samonis G, Falagas ME.

Lancet Infect Dis. 2018 Jan;18(1):108-120. doi: 10.1016/S1473-3099(17)30615-1. Epub 2017 Nov 5.

PMID:
29102324
18.

The dilemma of monotherapy or combination therapy in community-acquired pneumonia.

Vardakas KZ, Trigkidis KK, Apiranthiti KN, Falagas ME.

Eur J Clin Invest. 2017 Dec;47(12). doi: 10.1111/eci.12845. Epub 2017 Nov 9. Review.

PMID:
29027205
19.

CO2-laser for the genitourinary syndrome of menopause. How many laser sessions?

Athanasiou S, Pitsouni E, Falagas ME, Salvatore S, Grigoriadis T.

Maturitas. 2017 Oct;104:24-28. doi: 10.1016/j.maturitas.2017.07.007. Epub 2017 Jul 21.

PMID:
28923173
20.

Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis.

Pitsouni E, Grigoriadis T, Falagas ME, Salvatore S, Athanasiou S.

Maturitas. 2017 Sep;103:78-88. doi: 10.1016/j.maturitas.2017.06.029. Epub 2017 Jun 27. Review.

PMID:
28778337
21.

Resistance phenotypes and susceptibility of contemporary Serratia isolates in the university hospital of Crete, Greece.

Samonis G, Vardakas KZ, Maraki S, Stamouli P, Mavromanolaki VE, Kofteridis DP, Falagas ME.

Infect Dis (Lond). 2017 Nov - Dec;49(11-12):847-853. doi: 10.1080/23744235.2017.1361546. Epub 2017 Aug 2.

PMID:
28768448
22.

Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis.

Vardakas KZ, Voulgaris GL, Samonis G, Falagas ME.

Int J Antimicrob Agents. 2018 Jan;51(1):1-9. doi: 10.1016/j.ijantimicag.2017.05.016. Epub 2017 Jun 29. Review.

PMID:
28669836
23.

In vitro susceptibility and resistance phenotypes in contemporary Enterobacter isolates in a university hospital in Crete, Greece.

Maraki S, Vardakas KZ, Samonis G, Perdikis D, Mavromanolaki VE, Kofteridis DP, Falagas ME.

Future Microbiol. 2017 Jun;12:683-693. doi: 10.2217/fmb-2016-0216. Epub 2017 May 25.

PMID:
28540747
24.

Antibiotic prophylaxis for clean neck surgery.

Vamvakidis K, Rellos K, Tsourma M, Christoforides C, Anastasiou E, Zorbas KA, Arambatzi A, Falagas ME.

Ann R Coll Surg Engl. 2017 May;99(5):410-412. doi: 10.1308/rcsann.2017.0041.

25.

Continuous or Extended Intravenous Administration of β-Lactam Antibiotics.

Falagas ME, Vardakas KZ.

Am J Respir Crit Care Med. 2017 Apr 15;195(8):1077-1078. doi: 10.1164/rccm.201610-2004LE. No abstract available.

PMID:
28409679
26.

Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.

Falagas ME, Skalidis T, Vardakas KZ, Legakis NJ; Hellenic Cefiderocol Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. doi: 10.1093/jac/dkx049.

PMID:
28369471
27.

Aerococcus urinae, a cause of cystitis with malodorous urine in a child: clinical and microbiological challenges.

Skalidis T, Papaparaskevas J, Konstantinou D, Kapolou E, Falagas ME, Legakis N.

JMM Case Rep. 2017 Feb 28;4(2):e005083. doi: 10.1099/jmmcr.0.005083. eCollection 2017 Feb.

28.

In vitro susceptibility and resistance phenotypes in contemporary Citrobacter isolates in a University Hospital in Crete, Greece.

Maraki S, Vardakas KZ, Mavromanolaki VE, Kyriakidou M, Spais G, Kofteridis DP, Samonis G, Falagas ME.

Infect Dis (Lond). 2017 Jul;49(7):532-539. doi: 10.1080/23744235.2017.1297896. Epub 2017 Mar 9.

PMID:
28276281
29.

Early investigational antibiotics for the treatment of acute exacerbations of chronic bronchitis.

Falagas ME, Georgiou M.

Expert Opin Investig Drugs. 2017 Mar;26(3):313-317. doi: 10.1080/13543784.2017.1283402. Epub 2017 Jan 25. Review.

PMID:
28092467
30.

Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.

Vardakas KZ, Trigkidis KK, Falagas ME.

Clin Microbiol Infect. 2017 Apr;23(4):234-241. doi: 10.1016/j.cmi.2016.12.002. Epub 2016 Dec 10. Review.

31.

Women Physicians in Byzantium.

Gkegkes ID, Iavazzo C, Sardi TA, Falagas ME.

World J Surg. 2017 Mar;41(3):892-895. doi: 10.1007/s00268-016-3776-7.

PMID:
27847967
32.

Colistin loading dose: evaluation of the published pharmacokinetic and clinical data.

Vardakas KZ, Rellos K, Triarides NA, Falagas ME.

Int J Antimicrob Agents. 2016 Nov;48(5):475-484. doi: 10.1016/j.ijantimicag.2016.08.009. Epub 2016 Sep 28. Review.

PMID:
27743779
33.

Abnormal vaginal flora in symptomatic non-pregnant and pregnant women in a Greek hospital: a prospective study.

Tansarli GS, Skalidis T, Legakis NJ, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2017 Feb;36(2):227-232. doi: 10.1007/s10096-016-2787-5. Epub 2016 Oct 13.

PMID:
27738857
34.

Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.

Vardakas KZ, Falagas ME.

Int J Antimicrob Agents. 2017 Feb;49(2):233-238. doi: 10.1016/j.ijantimicag.2016.07.023. Epub 2016 Sep 16. Review.

PMID:
27686609
35.

The effect of microablative fractional CO2 laser on vaginal flora of postmenopausal women.

Athanasiou S, Pitsouni E, Antonopoulou S, Zacharakis D, Salvatore S, Falagas ME, Grigoriadis T.

Climacteric. 2016 Oct;19(5):512-8. doi: 10.1080/13697137.2016.1212006. Epub 2016 Aug 24.

PMID:
27558459
36.

Gentamicin-Collagen Sponges for the Prevention of Surgical Site Infections: A Meta-Analysis of Randomized Controlled Trials.

Konstantelias AA, Polyzos KA, Falagas ME.

Surg Infect (Larchmt). 2016 Oct;17(5):601-9. doi: 10.1089/sur.2016.025. Epub 2016 Jul 21. Review.

PMID:
27441956
37.

The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?

Falagas ME, Mavroudis AD, Vardakas KZ.

Expert Rev Anti Infect Ther. 2016 Aug;14(8):747-63. doi: 10.1080/14787210.2016.1204911. Review.

PMID:
27400643
38.

Impact of oseltamivir use on the reduction of complications in patients with influenza: a prospective study.

Vardakas KZ, Theocharis G, Tansarli GS, Rafailidis P, Falagas ME.

Arch Virol. 2016 Sep;161(9):2511-8. doi: 10.1007/s00705-016-2941-5. Epub 2016 Jul 1.

PMID:
27368992
39.

Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis.

Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME.

Int J Antimicrob Agents. 2016 Jul;48(1):1-10. doi: 10.1016/j.ijantimicag.2016.03.008. Epub 2016 Apr 27. Review.

PMID:
27216385
40.

Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature.

Vardakas KZ, Legakis NJ, Triarides N, Falagas ME.

Int J Antimicrob Agents. 2016 Apr;47(4):269-85. doi: 10.1016/j.ijantimicag.2016.02.001. Epub 2016 Feb 24. Review.

PMID:
27013000
41.

Fosfomycin.

Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ.

Clin Microbiol Rev. 2016 Apr;29(2):321-47. doi: 10.1128/CMR.00068-15. Review.

42.

Maternal Influenza Vaccination and Risk for Congenital Malformations: A Systematic Review and Meta-analysis.

Polyzos KA, Konstantelias AA, Pitsa CE, Falagas ME.

Obstet Gynecol. 2015 Nov;126(5):1075-84. doi: 10.1097/AOG.0000000000001068. Review.

PMID:
26444106
43.

The safety of polymyxin antibiotics.

Kelesidis T, Falagas ME.

Expert Opin Drug Saf. 2015;14(11):1687-701. doi: 10.1517/14740338.2015.1088520. Epub 2015 Sep 12. Review.

PMID:
26365594
44.

Rapid molecular diagnostic tests in patients with bacteremia: evaluation of their impact on decision making and clinical outcomes.

Vardakas KZ, Anifantaki FI, Trigkidis KK, Falagas ME.

Eur J Clin Microbiol Infect Dis. 2015 Nov;34(11):2149-60. doi: 10.1007/s10096-015-2466-y. Epub 2015 Sep 2. Review.

PMID:
26329038
45.

Medical training in Greece: A crisis in progress.

Makris GC, Trigkidis KK, Apiranthiti K, Malietzis G, Alexiou VG, Falagas ME.

Postgrad Med. 2015 Aug;127(6):591-9. doi: 10.1080/00325481.2015.1069167.

PMID:
26224209
46.

Trimethoprim/sulfamethoxazole for Acinetobacter spp.: A review of current microbiological and clinical evidence.

Falagas ME, Vardakas KZ, Roussos NS.

Int J Antimicrob Agents. 2015 Sep;46(3):231-41. doi: 10.1016/j.ijantimicag.2015.04.002. Epub 2015 May 15. Review.

PMID:
26070662
47.

Editorial Commentary: Fosfomycin: The Current Status of the Drug.

Falagas ME, Rafailidis PI.

Clin Infect Dis. 2015 Oct 1;61(7):1144-6. doi: 10.1093/cid/civ443. Epub 2015 Jun 10. No abstract available.

PMID:
26063717
48.

Susceptibility patterns of uropathogens identified in hospitalised children with community-acquired urinary tract infections in Thrace, Greece.

Mantadakis E, Vouloumanou EK, Panopoulou M, Tsouvala E, Tsalkidis A, Chatzimichael A, Falagas ME.

J Glob Antimicrob Resist. 2015 Jun;3(2):85-90. doi: 10.1016/j.jgar.2015.02.006. Epub 2015 Mar 28.

PMID:
27873675
49.

Clostridium difficile in Crete, Greece: epidemiology, microbiology and clinical disease.

Samonis G, Vardakas KZ, Tansarli GS, Dimopoulou D, Papadimitriou G, Kofteridis DP, Maraki S, Karanika M, Falagas ME.

Epidemiol Infect. 2016 Jan;144(1):161-70. doi: 10.1017/S0950268815000837. Epub 2015 May 20.

PMID:
25989816
50.

Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit.

Vardakas KZ, Matthaiou DK, Falagas ME, Antypa E, Koteli A, Antoniadou E.

Infect Dis (Lond). 2015;47(10):751-3. doi: 10.3109/23744235.2015.1049659. Epub 2015 May 19. No abstract available.

PMID:
25986909

Supplemental Content

Loading ...
Support Center